SCHEMBL30696789

SCHEMBL30696789

Cc1ccccc1C(=O)N1CCc2cc(-c3nc(NC(=O)Cc4cccc(OCCOCCOCCOCCOCCOCCOCCO)c4)sc3C)ccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.67
POLB P06746 2/20 0.67
MAFG O15525 1/20 0.67
HPGD P15428 1/20 0.67
NFE2L2 Q16236 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
LMNA P02545 5/20 0.58
HTT P42858 3/20 0.58
ALDH1A1 P00352 5/20 0.53
MAPT P10636 3/20 0.51
GAA P10253 1/20 0.51
NT5E P21589 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
USP2 O75604 1/20 0.44
GLS O94925 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ROCK2 O75116 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27353701 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696799 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696779 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL27353872 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696802 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696712 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696801 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696825 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL30696749 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2
SCHEMBL27353390 1.00 SMN1; SMN2 (0.67) SMN1; SMN2POLBMAFGHPGDNFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 EP disclosed
CN-119730847-A NRF2 protein degradation agent 盖尼米德肿瘤学股份有限公司 2025-03-28 CN disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 WO disclosed